Vedolizumab (Entyvio)
A gut-targeted biologic: how it works, drips and injections, side effects, and why NICE and the BSG now see it differently
In short
- Vedolizumab (brand Entyvio) is a 'gut-selective' biologic that blocks a protein called integrin on white blood cells.
- It starts as a drip in hospital and may later switch to injections at home.
- It can be slow: Crohn's & Colitis UK says it may take up to 14 weeks to work.
- Because it targets the gut, the overall risk of infection is thought to be lower than with some other biologics.
- NICE still recommends it after an anti-TNF; the 2025 BSG guideline does not routinely suggest it for moderate to severe Crohn's, but does suggest it after bowel surgery.
Get help if
Call 999 or go to A&E
- You have signs of a serious allergic reaction, such as difficulty breathing or swelling of your face, lips or throat. Crohn's & Colitis UK says to contact NHS 111 or call 999 straight away.
Urgent GP appointment or NHS 111
- You notice changes in your eyesight, difficulty speaking, new clumsiness or weakness, or memory loss or confusion. Crohn's & Colitis UK says to seek medical help immediately.
Contact your IBD team
- You have chills, a high temperature, a cough that will not go away, a rash or severe diarrhoea. Contact your doctor or IBD team immediately.
In an emergency call 999. For urgent advice call 111 or use 111 online. 1
On this page
What is vedolizumab and how does it work?
Vedolizumab is a biologic medicine, an antibody made by living cells in a lab. In Crohn's, too many white blood cells move from the blood into the gut and cause inflammation. Vedolizumab sticks to a protein called integrin on the surface of these cells, which stops them getting into the gut. Crohn's & Colitis UK describes it as a gut-selective integrin blocker, because it works on the gut rather than the whole body.12
Its brand name is Entyvio. It is licensed for adults; use in children is outside its licence, though a specialist may discuss it for under-18s when other treatments have not helped.1
Who is it for?
NICE recommends vedolizumab for moderate to severe Crohn's when an anti-TNF medicine (such as infliximab or adalimumab) has not worked, has stopped working, cannot be tolerated or is unsuitable. It should be given as a planned course and reassessed at 12 months. For people in complete remission at that point, NICE says stopping can be considered, with treatment restarted if Crohn's flares again.3
Crohn's & Colitis UK says that on the NHS, people with Crohn's can only have vedolizumab if an anti-TNF has failed or is unsuitable. A more recent NICE appraisal, of guselkumab, lists vedolizumab, risankizumab and guselkumab as options for a similar group of people, and says the least expensive suitable one should be chosen after discussion.14
Why does the BSG guideline see it differently?
This is one of the clearest differences between the two sets of UK guidance. The 2025 BSG guideline no longer suggests vedolizumab for bringing moderate to severe Crohn's under control or keeping it there. It based this on a Cochrane review of randomised trials. That review was confident that vedolizumab works better than a dummy treatment, but the extra benefit was modest: about 7 more people in every 100 reached remission when settling a flare, and about 14 more in every 100 stayed in remission. The BSG judged these effects to be very small for settling a flare and small for keeping Crohn's calm.56
A published review of the BSG guideline points out that non-randomised studies, which were not counted, have shown some people do well on it. It says vedolizumab probably still has a role for selected people, but that patients should be told their chance of responding is lower than with other medicines, and that the wider IBD team should agree before it is used.5
Confusingly, the same BSG guideline does suggest vedolizumab, along with infliximab and adalimumab, as a first option for preventing Crohn's returning after an ileocaecal resection (removal of the end of the small bowel and start of the large bowel). NICE's 2019 guideline says biologics should not be offered for that purpose after a complete resection. If vedolizumab is suggested for you, it is reasonable to ask your team why it is the best fit.57
How is it given, and how well does it work?
Vedolizumab is first given as a drip into a vein, usually in a hospital day unit. Crohn's & Colitis UK says each infusion takes about 30 minutes, and you will be watched for a while afterwards, longer after the first two. You will have at least two doses this way. After that, you may carry on with drips or switch to injections under the skin with a pre-filled pen or syringe, which you can learn to do at home.18
Injections are delivered to your home and kept in the fridge. The medicine can only be prescribed by a hospital specialist, not by your GP.1
Crohn's & Colitis UK calls vedolizumab slow to start for some people. Some feel better within six weeks, but in Crohn's it can take up to 14 weeks. If there is no improvement by then, your team may suggest stopping and trying something else.1
In the main trial, the share of people whose Crohn's was under control at six weeks was roughly double on vedolizumab compared with placebo. After a year, about 39 in 100 people on vedolizumab were in remission compared with 22 in 100 on placebo. Later studies of the injection showed similar results. The Cochrane review also found that overall side effects were probably similar to placebo.16
What checks will I need?
Before you start, your team will check for TB (with a blood test or chest X-ray), hepatitis and HIV, ask about chickenpox, shingles and cold sores, and make sure your vaccines are up to date. Tell them if you have ever taken natalizumab or rituximab. During treatment you will have regular reviews, and a full check-up after 12 months to decide whether to continue.1
What side effects can it cause?
Crohn's & Colitis UK describes vedolizumab as generally safe with low rates of side effects; in trials, side effects were about as common as with placebo. The most frequently reported were cold-like symptoms (sore throat, blocked or runny nose), joint pain and headaches. Others listed include chest or sinus infections, tummy bugs, skin changes such as itching or acne, bloating or piles, high blood pressure, night sweats, muscle pain and, rarely, liver inflammation.1
Because it works on the gut, the overall rate of infections, including chest infections and shingles, is likely to be lower than with other biologics, but gut infections may be a little more common. A medicine that works in a similar way has been linked to a rare brain infection called PML; Crohn's & Colitis UK says the risk with vedolizumab appears very small, with only one case reported in someone who had other risk factors. In trials, cancer rates were similar to those in people with IBD who did not take it.1
Vaccines, pregnancy and breastfeeding
Current advice is to avoid live vaccines while taking vedolizumab, and Crohn's & Colitis UK suggests waiting at least three months after the last dose, sometimes up to 12 months. The flu jab, pneumococcal and COVID-19 vaccines are not live and are safe.1
The manufacturer advises contraception during treatment and for about four to five months after stopping. Information on pregnancy is limited, but so far it has not been linked with problems, and experts consider it probably low risk; stopping may risk a flare. If you took it while pregnant, your baby's live vaccines may be delayed, so tell your baby's health team. It passes into breast milk only in low amounts and experts think breastfeeding is unlikely to harm your baby.1
Sources
This article is written in our own words from these sources. Each number in the text points to one of them.
- Crohn's & Colitis UK Vedolizumab Guide, May 2023 Read on the Crohn's & Colitis UK website: Vedolizumab
- Crohn's & Colitis UK Biologic medicines and other targeted treatments Guide, Jul 2023 Read on the Crohn's & Colitis UK website: Biologic medicines and other targeted treatments
- NICE Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy (TA352) Guideline, Aug 2015 Read on the NICE website: Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy (TA352)
- NICE Guselkumab for previously treated moderately to severely active Crohn's disease (TA1095) Guideline, Aug 2025 Read on the NICE website: Guselkumab for previously treated moderately to severely active Crohn's disease (TA1095)
- Frontline Gastroenterology (via PMC) Guideline review: 2025 British Society of Gastroenterology guidelines on inflammatory bowel disease in adults - Part 1: Crohn's disease Guide, Nov 2025 Read the paper: Guideline review: 2025 British Society of Gastroenterology guidelines on inflammatory bowel disease in adults - Part 1: Crohn's disease
- Cochrane Vedolizumab for induction and maintenance of remission in Crohn's disease Systematic review, Jul 2023 Read the review: Vedolizumab for induction and maintenance of remission in Crohn's disease
- NICE Crohn's disease: management - Recommendations Guideline, May 2019 Read on the NICE website: Crohn's disease: management - Recommendations
- Royal Free London NHS Foundation Trust Starting biologic medication Leaflet, Aug 2025 Read the Royal Free London NHS Foundation Trust leaflet: Starting biologic medication